Resources

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s RC Claim Assist solution.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s Rapid Response solution.

Learn more about MMIT’s Engage solution.

Learn the causes of rebate leakage and how MMIT’s Contract Validation solution can provide a workflow automation platform that enables manufacturers to validate formulary positioning at scale.

RJ Health, an MMIT company, conducted a survey on NDC mandates. In 2016 and 2021, we asked payers questions such as how they are managing NDCs and who performs unit conversions. We compiled these results

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s Bridging as a Service solution.

Inform site selection, drive trial awareness and enrollment, and uncover patient-centric signals for evidence generation and outcomes studies.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

How MMIT’s longstanding advisory relationship with a global pharmaceutical company helped transform its portfolio strategy.

Learn how pharma companies that were early adopters of MMIT’s FormTrak integration in Veeva CRM see the new functionality changing their workflow.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Understanding and maintaining insight into payer enrollment is difficult. At MMIT, we are focused on helping our clients understand the complex payer landscape.

How Medical Billing and Coding Can Impact Patient Access. Hear from the experts from RJ Health, an MMIT company.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn more about MMIT’s proactive, economic, precise, and comprehensive solution that can help manufacturers promote their therapies to specific providers using lab test results before a diagnosis and/or prescribing decision is made.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn more about MMIT’s Surveillance solution.

PULSE Provider includes clinical pathway information for IDNs that create and maintain their own pathways.

PULSE Pathways includes data on third parties that develop pathways for IDNs and payers.

Learn how Patient Access Analytics from MMIT and Panalgo can show how coverage decisions influence physician prescriber behavior.

Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Read a summary of the Patient Access Analytics solution from MMIT and Panalgo.

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

Learn how MMIT and MarketLauncher helped a medtech company engage a difficult-to-reach health plan audience.

Learn more about MMIT’s Formulary Navigator solution.

You need a variety of resources to develop a successful payer strategy. Download our infographic to learn how MMIT can help your organization.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn how RJ Health helped a niche healthcare company bolster its payer communications.

Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.

Learn how a healthcare services company partnered with MMIT to help support its provider network with coverage data.

Contract Validation is a workflow automation platform that enables manufacturers to validate formulary positioning at scale by crosschecking the contract language against MMIT’s industry-leading data.

MMIT’s FormTrak tool helps prescribers get their patients on the right therapy even amid complex drug coverage requirements. FormTrak’s integration in Veeva CRM, pharma field teams can deliver an access message right in Veeva’s platform.

Learn more about how MMIT’s FormTrak solution can help your team.

Learn more about how MMIT’s FormTrak solution can help your team.

Learn more about how MMIT’s FormTrak solution can help your team.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

MMIT’s new FormTrak integration in Veeva CRM changes how pharma companies detail healthcare providers. Now your field teams can access FormTrak seamlessly within Veeva thanks to the first native market access integration.

Learn how a small pharma company leveraged MMIT’s Analytics platform to drive its messaging with healthcare providers as it launched its first commercial product at the start of the COVID-19 pandemic.

Learn more about MMIT’s FormTrak integration with Veeva CRM.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market.

Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers.

Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and marketing team is crucial.

Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards and real-time alerts.

Without the right tools, your account managers will face many obstacles trying to win more pharma business. We’ll give you our top tips on how to engage with pharma manufacturers and differentiate your organization.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

Learn how formularies are currently managed, examine some of the key challenges faced by payers and PBMs, and evaluate new integrated solutions to optimize management of both pharmacy and medically covered drugs.

Learn how a pharma company leveraged MMIT’s advisory board service to get unique insights from payers and physician key opinion leaders (KOLs) to support its drug launch.

Learn how a pharma company’s market access team leveraged MMIT’s quantitative online surveys to obtain a custom pricing and contracting study to support its drug launch.

Factors complicate the payer enrollment landscape, making it challenging to project membership rolls across payers, geographies and channels. See enrollment projections, the drivers behind them and what you can expect from the 2021 payer landscape.

Learn how a medical device company partnered with and leveraged MMIT’s Payer Landscape data.

Learn how claims reimbursement is currently being managed, as well as some best practices for leveraging specialty drug data to streamline the process.

Learn how a healthcare IT organization was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Learn how a healthcare IT organization automated payer account identification and outreach.

Take a look into how a PBM was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

As specialty pharmaceuticals consume an ever-larger share of healthcare benefit dollars, payers, providers and other healthcare organizations are realizing the importance of managing drugs administered under the medical benefit, which most often are specialty drugs.

Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.

Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.

Take a look into how a specialty pharmacy partnered with MMIT to enhance its referral process and decrease time to therapy for patients.

MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

View a demo of the Payer Landscape tool.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.